Managing the Risks of Medicines: An Examination of FDA’s Application of Criteria for Requiring a REMS

Abstract

Background:

In September 2016, the Food and Drug Administration (FDA) published a draft guidance for industry, FDA’s Application of Statutory Factors in Determining When a REMS Is Necessary, that detailed the factors the Agency considers in determining when a Risk Evaluation and Mitigation Strategy (REMS) is necessary. The objective of this study was to determine how the FDA has applied these criteria for newly approved drugs.

Methods:

For the 3-year period, 2015-2017, which included a full year of FDA approvals both before and after the issuance of the draft guidance, publicly available FDA reviews were analyzed for all 113 approved products using the criteria outlined in the guidance.

Results:

Of the 113 products approved, 5 required a REMS. The most cited reasons for not requiring a REMS for the remaining 108 drugs were that risks could be managed via professional labeling (87%), physicians (primarily specialists) were familiar with the management of the risks (76%), the risk profile was similar to other non-REMS marketed products (45%), products were used in a controlled setting (inpatient, infusion center) (30%), and/or safety concerns would be further evaluated by a postmarket study (14%).

Conclusions:

A review of Agency risk evaluations indicate that whether physicians are sufficiently familiar with and capable of managing a risk and that the health care setting where the product is administered is conducive to such management are leading factors in determining whether or not to require a REMS.

Keywords

drug safety risk management risk-benefit statutory factors risk mitigation review

Get full access to this article

View all access options for this article.

References

Public Law 110-85. Food and Drug Administration Amendments Act (FDAAA) of 2007. Title IX, Subtitle A, Section 505-1. Enhanced Authorities Regarding Postmarket Safety of Drugs, Risk Evaluation and Mitigation Strategies. https://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf. Published September 27, 2007.

Cronin

Berger

Seligman

. Risk evaluation and mitigation strategies with elements to assure safe use—alignment of the goals with the tools to manage risk. Therapeutic Innovation & Regulatory Science. 2014;48(6):724–733.

US Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS). https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm.

US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. FDA’s Application of Statutory Factors in Determining When a REMS Is Necessary—Guidance for Industry. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM521504.pdf. Published September 2016.

US Food and Drug Administration, Center for Drug Evaluation and Research. Advancing Health through Innovation—2017 New Drug Therapy Approvals. https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ReportsBudgets/UCM591976.pdf. Published January 2018.

US Food and Drug Administration, Center for Drug Evaluation and Research. 2016 Novel Drugs Summary. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM536693.pdf. Published January 2017.

US Food & Drug Administration. Center for Drug Evaluation and Research. 2015 Novel Drugs Summary. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm474696.htm. Published January 2016.

Smith

Seligman

. New opportunities for integrating drug safety risk management programs into the health care system—bridging the divide. JAMA. 2015;314(17):1793–1794.

US Department of Health and Human Services, Food and Drug Administration. Managing the risks from medical product use—creating a risk management framework. A Report to the FDA Commissioner from the Task Force on Risk Management. 5 1999.